KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Non Operating Income (2016 - 2025)

Boston Scientific's Non Operating Income history spans 17 years, with the latest figure at -$110.0 million for Q3 2025.

  • For Q3 2025, Non Operating Income changed N/A year-over-year to -$110.0 million; the TTM value through Sep 2025 reached -$287.0 million, changed N/A, while the annual FY2025 figure was -$228.0 million, 28.97% up from the prior year.
  • Non Operating Income for Q3 2025 was -$110.0 million at Boston Scientific, down from -$100.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $95.0 million in Q3 2021 and bottomed at -$412.0 million in Q4 2022.
  • The 5-year median for Non Operating Income is -$83.0 million (2023), against an average of -$101.1 million.
  • The largest annual shift saw Non Operating Income plummeted 1684.62% in 2022 before it soared 104.65% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $26.0 million in 2021, then tumbled by 1684.62% to -$412.0 million in 2022, then skyrocketed by 80.83% to -$79.0 million in 2023, then decreased by 26.58% to -$100.0 million in 2024, then dropped by 10.0% to -$110.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Non Operating Income are -$110.0 million (Q3 2025), -$100.0 million (Q2 2024), and $2.0 million (Q1 2024).